A Plus Biotechnology Co., Ltd. (TPE:6918)
Taiwan · Delayed Price · Currency is TWD 68.80
-1.30 (-1.85%)
Jul 30, 2026, 1:30 PM CST
A Plus Biotechnology Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 2,388 | 2,956 | 2,444 | 1,380 | - | - | |
Market Cap Growth | -32.60% | 20.95% | 77.04% | - | - | - |
Enterprise Value | 1,952 | 2,465 | 2,205 | 1,246 | - | - |
Last Close Price | 70.10 | 80.47 | 72.81 | 39.88 | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
PE Ratio | 13.69 | 17.45 | 16.18 | - | - | - |
PS Ratio | 2.78 | 3.54 | 3.18 | 2.05 | - | - |
PB Ratio | 2.09 | 2.34 | 2.66 | 1.67 | - | - |
P/TBV Ratio | 2.10 | 2.35 | 2.68 | 1.68 | - | - |
P/FCF Ratio | 103.05 | 20.41 | 16.07 | 9.22 | - | - |
P/OCF Ratio | 15.09 | 18.60 | 15.18 | 8.68 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
EV/Sales Ratio | 2.27 | 2.95 | 2.87 | 1.85 | - | - |
EV/EBITDA Ratio | 8.05 | 10.96 | 11.17 | 6.87 | - | - |
EV/EBIT Ratio | 9.02 | 11.81 | 12.08 | 7.44 | - | - |
EV/FCF Ratio | 84.20 | 17.02 | 14.50 | 8.32 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Debt / Equity Ratio | 0.15 | 0.08 | 0.12 | 0.14 | 0.24 | 0.05 |
Debt / EBITDA Ratio | 0.73 | 0.41 | 0.52 | 0.59 | 3.01 | 0.57 |
Debt / FCF Ratio | 7.40 | 0.66 | 0.70 | 0.76 | - | 0.36 |
Net Debt / Equity Ratio | -0.38 | -0.40 | -0.31 | -0.25 | -0.12 | -0.33 |
Net Debt / EBITDA Ratio | -1.95 | -2.28 | -1.44 | -1.14 | -1.48 | -3.70 |
Net Debt / FCF Ratio | -18.97 | -3.54 | -1.87 | -1.38 | 0.60 | -2.34 |
Asset Turnover | 0.59 | 0.61 | 0.68 | - | 0.51 | - |
Inventory Turnover | 0.84 | 0.82 | 0.82 | - | 0.68 | - |
Quick Ratio | 2.08 | 3.97 | 3.52 | 3.24 | 2.18 | 2.77 |
Current Ratio | 3.16 | 5.99 | 5.49 | 5.39 | 3.74 | 4.64 |
Return on Equity (ROE) | 17.46% | 15.52% | 17.29% | - | 4.41% | - |
Return on Assets (ROA) | 8.94% | 9.57% | 10.14% | - | 2.73% | - |
Return on Invested Capital (ROIC) | 22.43% | 23.59% | 23.39% | -91.37% | 5.72% | 6.68% |
Return on Capital Employed (ROCE) | 16.00% | 15.40% | 18.00% | 18.00% | 4.70% | 5.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Earnings Yield | 7.25% | 5.73% | 6.18% | -0.82% | - | - |
FCF Yield | 0.97% | 4.90% | 6.22% | 10.85% | - | - |
Dividend Yield | 6.97% | 6.21% | 5.49% | 6.77% | - | - |
Payout Ratio | 70.35% | 71.96% | 53.95% | - | 43.48% | - |
Buyback Yield / Dilution | -11.11% | -8.36% | -0.37% | -4.70% | -0.95% | - |
Total Shareholder Return | -4.18% | -2.15% | 5.12% | 2.07% | -0.95% | - |